Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus

This study has been completed.
Information provided by:
Dexa Medica Group Identifier:
First received: October 28, 2009
Last updated: September 26, 2010
Last verified: September 2010
The purpose of this study is to investigate clinical efficacy and safety of DLBS 32 in the management of subjects with type-II-diabetes mellitus and to determine the minimal effective dose of DLBS 32 for subjects with type-II-diabetes mellitus.

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: DLBS-32
Drug: Placebo capsule
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase-II Clinical Study: A Randomized, Double Blind, Dose Ranging, and Controlled Study to Evaluate the Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus

Further study details as provided by Dexa Medica Group:

Primary Outcome Measures:
  • Reduction of venous Fasting Plasma Glucose from baseline [ Time Frame: every 2-week interval over 6 weeks of treatment ]

Secondary Outcome Measures:
  • Reduction of 2h-post-prandial plasma glucose from baseline [ Time Frame: six weeks ]
  • Change of homeostasis model assessment of insulin resistance (HOMA-IR) from baseline [ Time Frame: six weeks ]
  • Change of high sensitivity C-reactive protein (hs-CRP) from baseline [ Time Frame: six weeks ]
  • Liver Function, Renal Function, Adverse events [ Time Frame: six weeks ]
  • Change in HbA1c from baseline [ Time Frame: six weeks ]
  • Change in lipid profile from baseline [ Time Frame: six weeks ]

Enrollment: 72
Study Start Date: October 2009
Study Completion Date: August 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment I Drug: DLBS-32
DLBS-32 50 mg once daily and lifestyle modification
Experimental: Treatment II Drug: DLBS-32
DLBS-32 100 mg once daily and lifestyle modification
Experimental: Treatment III Drug: DLBS-32
DLBS-32 200 mg once daily and lifestyle modification
Experimental: Treatment IV Drug: DLBS-32
DLBS-32 300 mg once daily and lifestyle modification
Placebo Comparator: Placebo Drug: Placebo capsule
Placebo capsules once daily and lifestyle modification


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Fasting capillary blood glucose of 127-249 mg/dL at screening
  • BMI >= 18.5 kg/m^2 or waist circumference of >= 90 cm (male) or >= 80 cm (female)
  • Normal liver function
  • Normal renal function
  • OHA-naive type-II-diabetic patients

Exclusion Criteria:

  • Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
  • Uncontrolled hypertension
  • History of or current treatment with insulin
  • Current treatment with systemic corticosteroids or herbal (alternative) medicines
  • History of renal and/or liver disease
  • Pregnant or breast feeding females
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01005069

Sanglah Hospital Denpasar
Denpasar, Bali, Indonesia
RSUD Tarakan
Jakarta Pusat, DKI Jakarta, Indonesia
Sponsors and Collaborators
Dexa Medica Group
Principal Investigator: Ketut Suastika, Prof. Dr. Division of Endocrinology and Metabolic Disease University of Udayana / Sanglah Denpasar Hospital
Principal Investigator: Nuniek E Nugrahini, Dr. Department of internal medicine, RSUD Tarakan
  More Information Identifier: NCT01005069     History of Changes
Other Study ID Numbers: DLBS-32-0309
Study First Received: October 28, 2009
Last Updated: September 26, 2010

Keywords provided by Dexa Medica Group:
diabetes mellitus
fasting plasma glucose
insulin resistance

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on May 25, 2017